Navigation Links
Neutropenia: Biosimilar Product from India Moves One Step Closer to European Market
Date:4/7/2008

VIENNA, Austria, April 7 /PRNewswire/ -- A biosimilar product for treating the negative effects that cancer chemotherapy can have on the white blood cells of patients is safe and exhibits an identical pharmacokinetic and pharmacodynamic profile compared to a reference product. This is the result of a clinical phase I trial conducted jointly by the Austrian company Kwizda Pharma GmbH and the Indian manufacturer INTAS Biopharmaceuticals Ltd. (IBPL). Upon completion of an upcoming clinical phase III trial, both companies will lodge an application to get the product approved for the European market. The market launch is planned for early 2010.

Neutropenia - a condition whereby the concentration of neutrophils (a type of white blood cell) in the blood is too low - is a serious side effect of cancer chemotherapy and can prevent the treatment from being successful. Granulocyte colony stimulating factor (G-CSF) is a human protein that can reverse neutropenia by initiating the production of neutrophils. Recombinant forms of the protein have already been approved for the European market. However, due to the high costs that are involved, the relevant authority (EMEA) is encouraging applications for biosimilar products.

Similar & Identical

Working in partnership with IBPL, the first and only biopharmaceutical company in India to comply with EU Good Manufacturing Practice (GMP), Kwizda Pharma has now completed a clinical phase I trial as part of the European application process for a biosimilar form of recombinant G-CSF known as Neukine. Neukine exhibits identical efficacy to the EU-approved reference product. Dr. Helmut Brunar, VP of Research & Business Development at Kwizda Pharma sums up the results of the trial: "Not only was Neukine cleared from the patients' blood plasma just as quickly as the reference, but the number of neutrophils also increased with identical kinetics after treatment. We are very pleased with these results." The study was a
'/>"/>

SOURCE Kwizda Pharma GmbH
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update
2. MAP Pharmaceuticals Reports Positive Results From Comparative Pharmacokinetic Trial for its Pediatric Asthma Product Candidate
3. Increasing Dairy Milk Production with Electrolyzed Drinking Water
4. Nuvelo Announces Phase 2 SONOMA-3 Trial Did Not Meet Target Product Profile and Discontinues Alfimeprase Development
5. Ception Therapeutics Initiates Phase II/III Clinical Trial for Its Lead Product Reslizumab in Eosinophilic Esophagitis (EE) in Children
6. ATS Medical Announces Initial Clinical Results of Stand-Alone Atrial Fibrillation Procedures Using ATS CryoMaze Product Line
7. On Second Anniversary, Compendia Bioscience Announces Significant Revenue Growth, Completion of Product Milestone and Expansion of Pharma Customer Commitments
8. Horizon Therapeutics Completes Enrollment in Phase 3 Trials for Lead Product Candidate HZT-501
9. Data Demonstrate that Obagi Medical Products Condition & Enhance Skin Care System is an Effective Complement to Facial Rejuvenation Procedures
10. Surgex(TM) Becomes the First and Only BSCG (Banned Substance Control Group) Certified Product Which is Clinically Proven Effective in Sports Recovery and Performance
11. IDM Pharma Announces Non-Binding Opinion of the European Committee for Medicinal Products for Human Use (CHMP) that Mifamurtide (L-MTP-PE) Provides a Possible Clinical Benefit in Survival
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... ST. LOUIS , July 22, 2014  According ... the time their children spend on digital devices. An ... the ages of 10 and 17 estimate they use ... day. However, a separate AOA survey of parents revealed ... use an electronic device for that same amount of ...
(Date:7/22/2014)... July 22, 2014  Vernalis plc (LSE: VER) and Tris ... (POC) for CCP-08, the third programme to achieve ... collaboration. Under this collaboration, POC requires the successful ... pilot comparative study against an immediate release reference ... will make a milestone payment to Tris. ...
(Date:7/22/2014)... PORT WASHINGTON, New York , ... Neue Partnerschaft für umfassenden ... gefährlichen Medikamenteneinwirkungen in Österreich    ... führender Anbieter von geschlossenen Transfersystemen (Closed System ... Medikus , einen Vertriebshändler und ...
Breaking Medicine Technology:Survey Reveals Parents Drastically Underestimate the Time Kids Spend on Electronic Devices 2Survey Reveals Parents Drastically Underestimate the Time Kids Spend on Electronic Devices 3Survey Reveals Parents Drastically Underestimate the Time Kids Spend on Electronic Devices 4Third Product in Vernalis' Cough Cold Pipeline (CCP-08) Achieves Proof-of-Concept 2Third Product in Vernalis' Cough Cold Pipeline (CCP-08) Achieves Proof-of-Concept 3Equashield ernennt Medikus zu seinem exklusiven österreichischen Vertriebspartner für seine geschlossenen Arzneimitteltransfersysteme 2
(Date:7/22/2014)... 2014 Cloud+MD Office 2.0 ... suite of medical software and services, designed by ... that produces “Actionable Information” to help Independent Physician ... and Billing Services optimize a wide range of ... Greater Efficiency, Noticeable Cost Reductions and Better Patient ...
(Date:7/22/2014)... For the past nine years, the ... working in tandem to help thousands of cancer patients ... care, and help survivors connect to resources dealing with ... their partnership to include referrals from PAF to LIVESTRONG ... other practical, emotional, and financial issues that accompany a ...
(Date:7/22/2014)... Joining Conquer Paralysis Now as its first champion in ... Paralympic silver medalist and quadriplegic Jennifer French. , As a ... a spinal cord injury in 1998. Now, she has joined ... , “People define cure differently,” French said. “For some, it’s ... the image in our minds of what we were like ...
(Date:7/22/2014)... July 22, 2014 Altec Products, ... workflow solutions, announced today their Gold Sponsorship of ... at Mandalay Bay Hotel and Casino in Las Vegas, ... Summit draws thousands interested in taking advantage of the ... to solve business problems and educate themselves on the ...
(Date:7/22/2014)... Bramal LED announced that they will be ... Jr, airing later this year via Discovery Channel. Dates and ... about Bramal LED’s T-10 lamps, which provide over 80,000 hours ... to 70 percent. Bramal LED’s T-10 lamps can be plugged ... or on direct AC voltage, with no need for an ...
Breaking Medicine News(10 mins):Health News:Cloud-MD Software will soon Receive MU2 Certification 2Health News:LIVESTRONG Foundation and Patient Advocate Foundation Expand Partnership to Support the Needs of Cancer Patients and Survivors Nationwide 2Health News:LIVESTRONG Foundation and Patient Advocate Foundation Expand Partnership to Support the Needs of Cancer Patients and Survivors Nationwide 3Health News:Paralympian Jen French Announced as Conquer Paralysis Now’s First Champion 2Health News:Altec Announces Gold Sponsorship of Sage Summit 2014 2Health News:Altec Announces Gold Sponsorship of Sage Summit 2014 3Health News:Bramal LED to be featured in Upcoming Episode of Innovations with Ed Begley, Jr. 2
... joint becomes inflamed. Treatment is often difficult and recovery ... the pain of this common condition. ,Now, an ... with extracorporeal shock wave therapy. During the therapy, ultrasound ... takes two to three 20-minute shock wave treatments to ...
... located at the base of the hair follicle. Hair ... In many people with hair loss, however, // the ... of abnormal follicles entering longer resting phases and producing ... University of Pennsylvania School of Medicine have isolated stem ...
... say there could be a new way to help prevent ... // increase high-density lipoprotein levels, also known as good cholesterol. ... for heart disease. They are commonly used to lower low-density ... target is a low level of good cholesterol. In fact, ...
... Toronto conducted a study to examine whether current procedures ... antibiotics // unnecessarily. Out of an estimated 6.7 million ... Doctors also researched the use of throat cultures and ... who were prompted to seek medical help for their ...
... attention deficit/hyperactivity disorder (ADHD) affects up to 12 percent of ... increased attention problems at age 7 among kids was seen ... toddlers.The study tracked the number of hours kids watched television ... two hours of television a day. Three-year-olds watched about three ...
... warnings from the Food and Drug Administration may leave ... what they claim.// ,Some of the products ... Blocker, and Zone Fat Blocker.Many of these supplements claim ... consumers to lose weight without making any lifestyle changes. ...
Cached Medicine News:
Long handle occluder - Black...
Double Ended Occluders...
Double Ended Occluders...
Designed to provide occlusion while permitting observation of the eye. Helpful to determine if only one eye is deviating. Approximately 9 inches long....
Medicine Products: